Clinical safety and effectiveness of the Genoss drug-eluting stent in real-world clinical practiceopen access
- Authors
- Youn, Young Jin; Lee, Jun-Won; Ahn, Sung Gyun; Lee, Seung-Hwan; Yoon, Junghan; Park, Jae Hyoung; Yoo, Sang-Yong; Kang, Woong Chol; Lee, Nam Ho; Kwon, Ki Hwan; Doh, Joon Hyung; Lim, Sang-Wook; Jang, Yang Soo; Jeon, Dong Woon; Heo, Jung Ho; Choi, Woong Gil; Cho, Sungsoo; Lee, Bong-Ki; Jeong, Hyonju; Hong, Bum-Kee; Choi, Hyun-Hee
- Issue Date
- Sep-2023
- Publisher
- KOREAN ASSOC INTERNAL MEDICINE
- Keywords
- Drug-eluting stents; Percutaneous coronary intervention; Prospective studies; Registries
- Citation
- KOREAN JOURNAL OF INTERNAL MEDICINE, v.38, no.5, pp 683 - 691
- Pages
- 9
- Journal Title
- KOREAN JOURNAL OF INTERNAL MEDICINE
- Volume
- 38
- Number
- 5
- Start Page
- 683
- End Page
- 691
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/90395
- DOI
- 10.3904/kjim.2023.129
- ISSN
- 1226-3303
2005-6648
- Abstract
- Background/Aims: The Genoss DESTM is a novel, biodegradable, polymer-coated, sirolimus-eluting stent with a cobalt-chromium stent platform and thin strut. Although the safety and effectiveness of this stent have been previously investigated, real-world clinical outcomes data are lacking. Therefore, the aim of this prospective, multicenter trial was to evaluate the clinical safety and effectiveness of the Genoss DESTM in all-comer patients undergoing percutaneous coronary intervention.Methods: The Genoss DES registry is a prospective, single-arm, observational trial for evaluation of clinical outcomes after Genoss DESTM implantation in all-comer patients undergoing percutaneous coronary intervention from 17 sites in South Korea. The primary endpoint was a device-oriented composite outcome of cardiac death, target vessel-related myocardial infarction (MI), and clinically driven target lesion revascularization (TLR) at 12 months.Results: A total of 1,999 patients (66.4 & PLUSMN; 11.1 years of age; 72.8% male) were analyzed. At baseline, 62.8% and 36.7% of patients had hypertension and diabetes, respectively. The implanted stent number, diameter, and length per patient were 1.5 & PLUSMN; 0.8, 3.1 & PLUSMN; 0.5 mm, and 37.0 & PLUSMN; 25.0 mm, respectively. The primary endpoint occurred in 1.8% patients, with a cardiac death rate of 1.1%, target vessel-related MI rate of 0.2%, and clinically driven TLR rate of 0.8%.Conclusions: In this real-world registry, the Genoss DESTM demonstrated excellent safety and effectiveness at 12 months among all-comer patients undergoing percutaneous coronary intervention. These findings suggest that the Genoss DESTM may be a viable treatment option for patients with coronary artery disease.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/90395)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.